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ABSTRACT

MOLECULAR GENETIC APPROACHES TO DISEASES OF NEURAL
DEVELOPMENT.
Mohamad Bydon, Kaya Bilguvar, Fatih Bayrakli, Luis Kolb, and Murat Gunel.
Department of Neurosurgery, Yale University School of Medicine, New Haven, CT.

This study utilized novel genetic techniques in order to find causative gene mutations that
underlie diseases of neural development. Our laboratory has collected 175 cases of
malformations of cortical development (MCD) from the United States and Europe. Four
of these cases are the focus of this manuscript: two familial cases of infantile
neuroaxonal dystrophy (INAD), a familial case of hereditary spastic paraparesis (HSP),
and a sporadic case of Greig cephalopolysyndactyly (GCPS) and cerebral cavernous
malformations (CCMs).

The techniques utilized to study the affected patients include microarray-based single
nucleotide polymorphism (SNP) genotyping and copy number variation (CNV) analysis,
both of which are powerful tools in the hunt for disease-causing gene mutations.

In the familial cases of INAD, we report two novel mutations in the PLA2G6 gene,
previously shown to cause INAD when mutated. In the familial case of HSP, we
demonstrate linkage to the SPG11 locus on chromosome 15q. Finally, in the sporadic

case of GCPS and CCM, we published the first report on this novel syndrome along with
a genetic analysis that demonstrates a microdeletion on chromosome 7p, resulting in
heterozygous loss of both the GLI3 and CCM2 genes.

The three studies presented in this manuscript demonstrate the utility of SNP genotyping
and CNV analysis in revealing the genetic mutations that underlie diseases of neural
development.
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INTRODUCTION

While humans share 99% of their DNA sequences, there are many examples of genetic
variation in the genome, ranging from large chromosomal abnormalities to insertions or
deletions of one or more nucleotides. It is believed that within the 3 billion bases of the
human genome, there are more than 10 million common nucleotide variations between
individuals (1). A single nucleotide variation occurs when a nucleotide – A, C, T, or G –
in an individual’s DNA is altered. For this variation to be considered a single nucleotide
polymorphism (SNP), it must occur in 1% of the population. The International
Haplotype Mapping Project (2) has identified more than 2 million SNP markers, which
can be used in large-scale genotyping.

SNPs, as well as other genetic variations, have become of great interest to the scientific
community because they are thought to predispose individuals to disease (3, 4).
Advances in SNP genotyping have been made possible by the development of
microarrays, membranes or glass slides on which probes – sequences of DNA – are fixed
in an orderly arrangement. Microarrays facilitate the detection of thousands of genomic
variants, including SNPs and more recently copy number variations, in a sample
simultaneously. Microarray-based methods for SNP genotyping (5) have been used in
linkage and association studies of complex disorders such as prostate cancer (6),
rheumatoid arthritis (7), erythrokeratodermia variabilis (8), bladder cancer (9), systemic
lupus erythematosus (10), and dyslipidemia (11) (Table 3).
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In addition to their utilization in SNP genotyping, microarray-based methods have been
used in the analysis of copy number variations (CNVs) spanning large chromosomal
regions (12). Sebat et al. (13) recently demonstrated the presence of CNVs, DNA
segments found throughout the human genome in varying numbers among individuals
because of deletions, insertions, or duplications. These CNVs are common in apparently
normal persons, but may also predispose toward or cause disease phenotypes (14).
Advances in molecular genetic techniques now allow CNV analysis using a variety of
microarray-based approaches including comparative genome hybridization (aCGH).

In recent years, SNP genotyping and CNV analysis have been utilized to identify gene
mutations responsible for malformations of cortical development. Our laboratory is
involved in ongoing efforts to uncover the genetic basis of disorders of cell proliferation,
neuronal migration, and cortical organization, as well as other syndromes of neural
development. Through national and international collaborations, our laboratory has
identified and collected DNA samples from patients and families afflicted with diseases
of neural development. Using both sporadic and familial cases, we have successfully
employed array-based SNP and CNV approaches to uncover several disease-causing
genetic mutations.

In Bayrakli et al. (15), our laboratory reported the case of a Turkish family in which 6
members were afflicted with autosomal recessive Parkinsonism. First, whole-genome
linkage analysis was performed using a microarray system that contains 56,860 SNP
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markers. The results of this initial genotyping demonstrated linkage to chromosome
6q26, the region housing the parkin gene (PARK2) (Figure 1). Mutations in PARK2 have
been shown to be associated with early-onset Parkinson’s disease (16). Array-based
comparative genome hybridization (aCGH) was then performed to determine the
presence of copy number variations (CNVs) in the DNA of an affected patient relative to
pooled human genomic DNA controls. The aCGH results revealed a homozygous
microdeletion in the same region of chromosome 6q26 (Figure 2). PCR amplification
within the predicted deleted region in 3 affected siblings and two unaffected relatives
confirmed the presence of a homozygous microdeletion in exon 5 of the PARK2 gene
(Figure 3).

The Bayrakli et al. (15) study demonstrates the utility of molecular genetic techniques in
identifying disease-causing gene mutations. Microarray-based SNP genotyping provided
evidence of linkage to chromosome 6q26. Comparative genome hybridization or CNV
analysis reaffirmed this locus as the region of interest and demonstrated a microdeletion
in the parkin gene. Finally, PCR amplification confirmed the presence of a homozygous
deletion in 3 affected siblings.

Molecular genetic techniques, including SNP genotyping and CNV analysis, have been
utilized by several research groups, including ours, to investigate the gene mutations that
underlie malformations of cortical development. These diseases and the genetic
breakthroughs associated with them will be the focus of this manuscript.

4
Malformations of Cortical Development

Advances in molecular genetics have led to the elucidation of causative genes behind
several human brain diseases. This has occurred concurrently with improved
radiographic methods used to diagnose these disorders. Prior to 1980, malformations of
cortical development (MCD) were studied by pathologists at autopsy. The advent of
magnetic resonance imaging (MRI) allowed for earlier detection of these diseases. For
the first time, phenotypic descriptions could be matched to radiologic findings. Interest
in MCD has grown since then as the disorders have become increasingly recognized as
significant causes of epilepsy, developmental delay, and other neurologic ailments.

Several proposed classification schemes have attempted to organize MCD based on our
growing understanding of brain development. In 1996, Barkovich et al. (17) published a
classification system that divided neural developmental pathology into disorders of cell
proliferation, neuronal migration, or cortical organization. These 3 events—proliferation,
migration, and organization—define embryonic cortical development. In the initial
phase, neurons and glial cells proliferate in the ventricular and subventricular zones,
respectively. Following the start of proliferation, postmitotic neurons migrate to the
cortical plate. Finally, within the cortex, neurons undergo a process of vertical and
horizontal organization as well as elaboration of their axonal and dendritic branches (18,
19).
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MCD can result from abnormalities in any of the 3 stages of cortical development. In the
initial classification (17), if a disease process involved more than one of the 3 stages, then
it was classified based on the first abnormal step. Additionally, the classification
separated diffuse and focal malformations because they were thought to have separate
pathophysiology. The classification was revised in 2001 (20) and then again in 2005 (21)
(Figure 1). In their most recent effort, the authors hoped to account for the rapid
accumulation of new information regarding the genetic basis of many diseases of neural
development. While the latest classification retains the 3 major groups of disorders
described previously, it incorporates new information on the gene mutations that cause
diseases of neural development (Figure 2).

The increased focus on the genetic basis of MCD allows for less reliance on the
phenotypic characteristics of these disorders. A gene-oriented classification is necessary
because mutations in different genes may result in the same phenotype, while various
mutations in one gene may result in different phenotypes (21). Many of the genetic
breakthroughs on MCD have occurred recently using novel molecular genetic approaches
(Figure 2). These approaches have been utilized by several research groups, including
ours, in order to uncover the genetic basis of disorders of cell proliferation, neuronal
migration, and cortical organization, as well as the malformations of cortical
development that are not otherwise classified.
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Disorders of Cell Proliferation

Diseases in this group may be due to abnormal proliferation or apoptosis, resulting in an
increase or decrease in the number of neurons or glial cells, or both (20). When the
proliferation or apoptosis is diffuse, it leads to an abnormality in brain size, otherwise
known as microcephaly or macrocephaly. Three main types of microcephalies occur:
microcephaly with normal to thin cortex, extreme microcephaly with thick cortex
(microlissencephaly), or microcephaly with extreme polymicrogyria (21). On the other
hand, localized proliferation causes abnormal cell growth without a change in brain size.
This set of disorders includes cortical hamartomas of tuberous sclerosis; cortical
dysplasia associated with epilepsy; hemimegalencephaly (enlargement of one hemisphere
leading to mental retardation and epilepsy); and neoplasms such as ganglioglioma,
gangliocytoma, or dysembryoplastic neuroepithelial tumor.

Recent studies have identified several gene mutations associated with disorders of cell
proliferation. Several genes have been shown to cause autosomal recessive
microcephaly, including MCPH1 on chromosome 8p23 (22), ASPM on 1q31 (23, 24),
CDK5RAP2 on 9q34 (25), CENPJ on 13q12.2 (25), and SLC25A19 on 17q25.3 (26).
The ATR gene on 3q22-24 has been found to cause Seckel syndrome or
microlissencephaly with short stature (24), while TSC1 (27, 28) and TSC2 (29, 30) on
9q32 and 16p13.3 were shown to cause cortical hamartomas of tuberous sclerosis.
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These findings illustrate that various gene mutations may lead to similar phenotypes.
Such investigations contribute significantly to our understanding of disorders of cell
proliferation. Our laboratory has collected 13 familial or sporadic cases of disorders in
this category including cortical dysplasia, microcephaly, and dysembryoplastic
neuroepithelial tumor (DNET), as well as syndromes like infantile neuroaxonal dystrophy
(INAD). We collected two familial cases of INAD and our genetic studies revealed two
novel mutations in the PLA2G6 gene, previously shown to be mutated in INAD. These
results will be discussed at length in this manuscript.

Disorders of Neuronal Migration

These diseases, resulting from abnormal migration of neurons from the ventricular zone
to the cerebral cortex, often present on MRI as gray matter in the subependymal or
subcortical regions (20). Malformations within this group include lissencephaly,
cobblestone complex, and heterotopia (21). Lissencephaly or “smooth brain” is
characterized by a lack of gyri, abnormally thick cortex, and enlarged ventricles.
Subcortical band heterotopia (SBH) consists of a subcortical band of gray matter
separated from the cortex by a band of white matter. Both diseases comprise the socalled agyria-pachygyria-band spectrum. Cobblestone complex refers to a “cobblestone”
cortex, abnormal white matter, large ventricles, and small brainstem and cerebellum (20).
It is associated with congenital muscular dystrophy syndromes (37). Finally, heterotopia
have various forms, ranging from periventricular to subcortical to marginal glioneuronal.
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Periventricular nodular heterotopia consist of small masses of gray matter that line the
ventricular walls and protrude into the lumen (38). Subcortical heterotopia (other than
band heterotopia, described above) are less common than periventricular heterotopia.
Depending on their size and location, subcortical heterotopia may result in developmental
delay or mental retardation, hemiplegia, or epilepsy (20).

Several genes have been implicated in disorders of neuronal migration. Several groups
have published gene mutations that underlie lissencephaly and subcortical band
heterotopia, including the DCX gene on Xq22.3-23 (39-41), ARX on Xp22.13 (42, 43),
LIS1 on 17p13.3 (44-46), RELN on 7q22 (47). Mutations in the LARGE gene on
22q12.3-13.1 (48), POMT1 on 9q34.1 (49), FKRP on 19q13.3 (50, 51), and FCMD on
9q31 (52) have been shown to cause various syndromes within the cobblestone complex,
while ARFGEF2 on 20q13.3 (53) and FLNA on Xq28 (54) are believed to mutated in
bilateral periventricular nodular heterotopia.

In this category, our laboratory has collected 42 cases of disorders, including heterotopia,
periventricular development anomalies, and lissencephaly, as well as syndromes like
hereditary spastic paraplegia (HSP). For this latter syndrome, we have uncovered novel
genetic findings based on a familial case of HSP. Specifically, we were able to
demonstrate linkage of our kindred to the SPG11 locus on chromosome 15q. While
SPG11 has been reported previously to be associated with cases of HSP, our results
confirm and narrow the locus.
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Disorders of Cortical Organization

Diseases in this category occur when neurons reach the cortex, but fail to form normal
cortical layers or connections. They typically have abnormal gyri with normal cortical
thickness (20). Common disorders include polymicrogyria (many small gyri separated by
shallow sulci), schizencephaly (polymicrogyria with clefts), cortical dysplasia without
balloon cells, and microdysgenesis (21). As with other MCD, these diseases typically
present with developmental delay, cognitive deficits, and epilepsy.

Much work remains to be done on the genetic basis of the disorders of cortical
organization. The only significant gene mutation identified has been that of GPR56 on
16q13 in bilateral frontoparietal polymicrogyria (67). Our laboratory has collected 55
cases of disorders in this category that includes cortical developmental anomalies,
polymicrogyria, and schizencephaly. These cases will allow us to shed us light on the
genetic variations that cause disorders of cortical organization. Recently, we published
the case of a patient with a disorder of cortical organization, Greig
cephalopolysyndactyly (GCPS), and cerebral cavernous malformations (CCM). Our
genetic studies uncovered a microdeletion in chromosome 7p, which resulted in the loss
of the GLI3 and CCM2 genes. While deletions in these two genes have been previously
shown to cause GCPS and CCM respectively, this is the first case in the literature of a
patient with deletions in both genes and the hallmarks of both diseases. To our
knowledge, the combination of GCPS and CCM represents a novel genetic syndrome,
one that will be discussed further in this manuscript.
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Malformations of Cortical Development, Not Otherwise Classified

This fourth category includes disorders that cannot be easily placed into the 3
aforementioned groups, including metabolic disorders, peroxisomal disorders, and
unclassified syndromes. We have collected 65 patients with various syndromes of neural
development, ranging from autism to childhood epilepsy.
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STATEMENT OF PURPOSE & SPECIFIC AIMS

The purpose of this study is to utilize molecular genetic techniques, specifically SNP
genotyping and CNV analysis, in order to find genetic mutations that cause diseases of
neural development. This manuscript details our studies on three diseases in particular:
INAD, HSP, and GCPS. Our aim is to uncover the gene mutations that cause these
disorders so that we may develop a better understanding of the pathophysiology of these
diseases specifically and malformations of neural development generally.
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METHODS

Patient Identification and Collection of Blood Samples

The author of this manuscript attained approval for this study from the Yale Human
Investigations Committee (Protocol 7680). The patients afflicted with MCD were
identified by physicians at Yale New Haven Hospital as well as collaborators at other
institutions in the United States and Europe. For patients identified at Yale New Haven
Hospital, the author attained consent and collected their blood samples. For patient
identified elsewhere, consent was attained and blood samples were collected by the
collaborating physicians.

Isolation of Genomic DNA

Total genomic DNA was isolated from lymphocyte nuclei using a procedure described by
Bell et al. (75). Ten milliliters of blood collected in a heparinized tube and then kept at
4°C was mixed with 90 ml of 0.32 M sucrose / 10 mM TrisHCl (pH 7.5) / 5 mM MgCl2 /
1% Triton X-100 at 4°C to lyse all cells. The nuclei were collected by centrifugation at
1000 X g for 10 min. The nuclear pellet was suspended in 4.5 ml of 0.075 M NaCl /
0.024 M EDTA (pH 8.0) with a Pasteur pipette. Then 0.5 ml of 5% sodium dodecyl
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sulfate and proteinase K at 2 mg/ml were added and the mixture was incubated for
approximately 12 hr at 37°C.

The digest was gently mixed with 5 ml of phenol saturated with 20 mM Tris HCl (pH
8.0). Five milliliters of chloroform / isoamyl alcohol (24:1, vol/vol) was added and
gentle mixing was continued. The phases were separated by centrifugation for 15 min at
1000 X g. The upper, aqueous, phase was removed and gently extracted with the
chloroform / isoamyl alcohol mixture. After centrifugation, the aqueous phase was
removed; 0.5 ml of 3 M sodium acetate and 11 ml of 100% ethanol (at room temperature)
were added. The DNA was precipitated by inverting the tube several times and then
removed with a Pasteur pipette and placed in 1 ml of 10 mM Tris HCl (pH 7.5) / 1 mM
EDTA. The DNA was allowed to dissolve at 4°C. From 10 ml of blood, 20-50 μg of
DNA was obtained. In cases where the yield is low, we incubate the DNA at -20°C in
the presence of ammonium acetate. Genomic DNA was isolated by the author and
laboratory technicians.

Single Nucleotide Polymorphism Genotyping

Genotyping was performed using the GeneChip Mapping 50K XbaI Array (Affymetrix
Inc., Santa Clara, CA) containing 56,860 single nucleotide polymorphism (SNP) markers
for genome-wide linkage analysis, according to the company’s protocols. Briefly, after
DNA was digested with XbaI, adapters were ligated to the product. Primers were then

14
used to amplify the product by PCR. Following purification, fragmentation, and labeling,
biotin-labeled DNA product was hybridized to the Array chip. Arrays were then washed,
stained, and scanned (76). Affymetrix Micro-Array Suite 5.0 software was utilized to
obtain raw microarray feature intensities, the results of which were processed to derive
SNP genotypes using the Affymetrix Genotyping Tools software package. SNP
genotyping was performed by laboratory technicians.

Genechip Data Analysis

The Genome Analysis programs provided by Affymetrix were used for basic analysis of
the Genechip data. Multipoint linkage analysis was performed using a UNIX-based
program (Chunky). This program, initially described by Nahed et al. (76), parses the data
into individual files that convey chromosome number, SNP markers, map distances,
genotype calls, and allele frequencies. Final linkage analysis was then performed using
Allegro software (DeCode Genetics, Inc) (77). We assumed an autosomal recessive
inheritance pattern and assigned a 70% to 99% penetrance and a phenocopy rate of 0.001.
Allele frequencies for the GeneChip SNPs were obtained from Affymetrix. Genechip
analysis was performed by the author and by laboratory personnel.
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Confirmation of Linkage Using Microsatellite Short Tandem Repeat Markers

Microsatellite short tandem repeat (STR) markers are used in order to fine map the
linkage interval. Genomic regions with LOD scores approaching the theoretical
maximum were further characterized and verified using STR markers within said regions
according to the physical map data from the University of California at Santa Cruz
(UCSC) Genome Browser (http://genome.ucsc.edu/index.html?org=Human). All
available members of the family, both affected and unaffected, were genotyped. This
strategy is often referred to as a 2-stage design in linkage analysis (78). All genotyping
for microsatellite analysis was performed using PCR, with detection of fluorescent
products on an ABI 3700 sequencer equipped with the Genescan and Genotyper software
(ABI, Norwalk, CT). The author was involved in choosing the STR markers utilized in
the confirmation of linkage. The PCR was performed by laboratory personnel.

Candidate Gene Mutational Analysis

Exon-intron boundaries of the candidate genes SPATA5L1 and SEMA6D within the
linked interval were determined based on the University of California at Santa Cruz
(UCSC) Genome Browser (NCBI Build 36.1). PCR primers were designed using
PRIMER3 (http://frodo.wi.mit.edu/cgi-bin/primer3/primer3_www.cgi). Exon amplicons
were amplified and sequenced using standard techniques. Mutational analysis was
performed by the author and by laboratory personnel.
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Array CGH for Copy Number Variant Analysis
Isolated DNA from the patients was submitted for whole genome and chromosomespecific aCGH analysis by high-resolution, tiled microarray (NimbleGen Systems,
Madison, WI) to determine copy number variations (CNVs). These arrays employ
385,000 probes spanning all non-repetitive regions of the human genome on a single
chip, tiling the full genome at a median probe spacing of 6,000 bp. The chromosomespecific arrays contain 385,000 oligomeric probes of lengths between 45–85mers with a
median probe spacing of 10 bp. Patient DNA was cohybridized with pooled control
DNA to determine copy number differences (deletions or amplifications) across the entire
genome. Array CGH was performed by laboratory personnel.

Array CGH Data Analysis

All arrays were scanned with a GenePix 4000B Scanner (Molecular Devices Corporation,
Sunnyvale, California) and normalized using QSPLINE (79) within the NimbleScan
software package (Nimblegen Inc., Madison, WI). The normalized intensities were
subsequently analyzed with the Circular Binary Segmentation (CBS) algorithm (80) to
determine the significant breakpoints in log2 intensities along the chromosomes. Using
average window sizes of 1X, 5X, 10X, and 20X (X=the median inter-probe distance), we
determined the possible segments of the genome that were different between our patients
and pooled, population-matched control samples. A segment (y) was considered to be
significant if y > 0.3 or y < -0.3.
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The normalized intensities were also analyzed with our Seed algorithm (Mason et al., in
preparation), which creates windowed 5-probe averages along the genome after removing
outlier data points (Dixon test) to detect additional small CNVs occasionally missed by
CBS. Two patients with large-scale, known duplications in their genome were used to
empirically determine a threshold for the Seed algorithm that kept sensitivity above 90%
and specificity above 99.99%. We considered segment (y) to be significant in Seed if y >
0.22 or y < -0.22. Array CGH data analysis was performed by the author and by
laboratory personnel.

Quantitative RT-PCR

Array CGH analysis results were confirmed with quantitative RT-PCR using the standard
curve method for absolute quantitation. Primers were designed using Primer Express
Software, version 2.0 (Applied Biosystems), with the following criteria: amplicon size of
80 to 200/250 bp, GC content of 20 to 80%, no more than two guanines or cytosines in
the primer 3’ end, and melting temperature (Tm) of 59 to 60°C. Finally, the Basic Local
Alignment Search Tool (http://www.ncbi.nlm.nih.gov/blast/) was used for these primers.

The experimental design and calculations were performed as described by Applied
Biosystems (User Bulletin #2). To determine copy number changes, fourfold ranges of
five different serial dilutions from five pooled normal control DNA samples were used.
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In addition, we used 5 ng of genomic DNA from the patient’s DNA and pooled normal
control DNA. The RT-PCRs were performed in triplicate for each reaction. The 15-μl
reactions contained 1X final concentration of Power SYBR Green PCR Master Mix (part
number 4367660, Applied Biosystems) and 400 nM of each primer (Invitrogen). Each
experiment was performed using a 384-well optical PCR plate and the Applied
Biosystems machine (model 7900HT) with default cycling conditions.

A standard curve was created using the calculated threshold cycle of each dilution for
each gene. Amplifications were performed on the same diluted samples using primers for
the reference and target genes. For all experimental samples, the target quantity was
determined from the standard curve and divided by the target quantity of the normal
reference DNA. To assess reaction specificity and to verify product identity, melting
curve analysis was performed following amplification. We used the standard curves with
an efficiency between 90% and 100%, which corresponds to a slope between 23.58 and
23.20. Quantitative PCR was performed by laboratory personnel.
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RESULTS

Malformations of Cortical Development

Patient Collection

Our laboratory has collected 175 cases of malformations of cortical development (MCD),
including 13 cases of disorders of cell proliferation, 42 cases of disorders of neuronal
migration, 55 cases of disorders of cortical organization, and 65 cases of MCD not
otherwise classified (Figure 4).

CNV Analysis

We are currently in the process of performing chip analysis on our samples (results not
shown) in order to find the rate of homozygous deletions, heterozygous deletions, and
amplifications relative to controls.

Disorders of Cell Proliferation

As stated earlier, our laboratory has collected 13 cases of disorders in this category,
including 3 cases of cortical dysplasia, 1 case of microcephaly, 8 cases of
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dysembryoplastic neuroepithelial tumor (DNET) as well as one familial case of infantile
neuroaxonal dystrophy (presented below).

Infantile Neuroaxonal Dystrophy

Background

Infantile neuroaxonal dystrophy (INAD) is an autosomal recessive neurodegenerative
disorder characterized by progressive motor and mental deterioration beginning in the
first or second year of life. Clinically, the disease includes bilateral pyramidal tract signs,
truncal hypotonia, and late-course spastic tetraplegia, blindness, and dementia (31).
Death usually occurs before the age of 10 years.

While the pathophysiology of INAD has not been definitively elucidated, it is believed
that defects in axonal transport (32) or synaptic transmission (33) lead to the histologic
findings of axonal swelling and “spheroid bodies” in the central and peripheral nervous
system.

MRI scanning of INAD patients has occasionally revealed iron accumulation in the
globus pallidus, leading some to hypothesize that a disturbance in iron protein function
plays an important role in the pathogenesis of this disease (34).
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Recently, two studies have implicated mutations in PLA2G6, a gene encoding calciumindependent phospholipase A2, as being associated with INAD. In the first study,
Morgan et al. identified 44 unique mutations in PLA2G6 in patients affected with INAD
and neurodegeneration with brain iron accumulation (NBIA) (35). In the second study,
Khateeb et al. reported the identification of a unique PLA2G6 mutation associated with
INAD in two Israeli Bedouin families (36). Our laboratory collected two Turkish
kindreds with INAD and found two novel mutations in PLA2G6.

Phenotype Assignment

Our laboratory collected two sporadic cases of INAD (Figure 5). In the first case, the
affected children, DY, presented at the age of 2 years old with complaints of loss of
ability to walk or speak and with foot abnormalities. DY also displayed signs of truncal
hypotonia, manifested by an inability to sit up straight without support. DY was
delivered at term in a normal spontaneous vaginal delivery. At six months, she was able
to crawl and sit without support. She was normal until the age of 2 years, when she
began deteriorating. At 3 years old, skin biopsy was performed, revealing distended
demyelinated nerves around sweat glands and blood vessels. The axons contained
granular, electron-dense material with occasional clefts, a histopathological finding
consistent with infantile neuroaxonal dystrophy. This patient’s sibling also had INAD
and died at the age of 7 years. Neither parent is affected with the disease, consistent with
an autosomal recessive trait.
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The second affected child, MM, presented at the age of 1.5 years with complaints of
losing ability to walk or speak. By the age of 1 year, the patient had been able to walk
and speak words. A few months later, the patient presented with deterioration of both
faculties. Skin biopsy revealed findings of distended axons with granular, electron dense
material, consistent with INAD. No other members of this family have been affected
with INAD.

The MRI scans on both patients showed no evidence of hypointensity in the globus
pallidus, indicating a lack of iron accumulation. Both scans demonstrated signs of
cerebellar atrophy on T2 weighted MRI as well a mild periventricular hyperintensity on
Flair imaging.

DNA Sequencing

Direct PLA2G6 sequencing using the DNA of the two affected children revealed two
novel mutations in exons 12 and 15 of the gene. Both mutations were single nucleotide
substitutions. In exon 12, an A → G mutation resulted in a substitution of arginine with
glycine. In exon 15, a C → T mutation resulted in a substitution of threonine with
methionine.
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Disorders of Neuronal Migration

Our laboratory has collected 42 familial and sporadic cases of disorders in this category.
These include 5 cases of heterotopia, 3 cases of periventricular developmental anomalies,
24 cases of lissencephaly, and a familial case of hereditary spastic paraplegia (presented
below).

Hereditary Spastic Paraparesis

Background

Hereditary spastic paraplegias (HSP), also known as familial spastic paraparesis (FSP),
are a genetically and clinically heterogeneous group of neurological disorders
characterized by progressive lower extremity spasticity. HSPs can be associated with
other neurological sequelae including neuropathy, retinopathy, dementia, icthyosis,
mental retardation, deafness and seizures (“complicated” form), or by upper motor
neuron findings including lower-extremity spasticity and neurogenic bladder alone
(“uncomplicated” form). The diagnosis is confirmed through neurological testing,
muscle biopsy, EMG, MRI, and detailed genetic history. The majority of HSP familial
forms reported to date, up to 80%, demonstrate autosomal dominant patterns of
expression, while the remainder demonstrate autosomal recessive and X-linked recessive
inheritance patterns (55-57).
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The first association of HSP with mental retardation and epilepsy, designated “SPERM”
(OMIM 182610), was reported as a novel genetic disorder with an autosomal dominant
pattern of inheritance (58). The family described was excluded from 8 previously
described autosomal dominant HSP loci by linkage (59). Other families with
complicated forms of HSP have been reported including an autosomal recessive form
with a relatively constant clinical presentation of pyramidal tract signs in the lower
extremities which progress to the upper extremities, gradual cognitive impairment, an
onset before age 20, and radiographic findings of thinning of the corpus callosum (CC)
and cortical atrophy known as HSP-TCC, or SPG11 (OMIM 604360) (60-66). Our
laboratory is preparing a manuscript describing a new family from Eastern Turkey with
autosomal recessive HSP associated with early-onset mental retardation, epilepsy and a
variably thinned corpus callosum on MRI demonstrating linkage to the SPG11 locus at
15q13-15 using both SNP genotyping and CNV analysis. This data, when added to those
previously reported, supports the notion that SPG11 is a phenotypically and genetically
heterogeneous disorder.

Phenotype Assessment

The family was identified in Southeastern Turkey after the index case, a product of a
consanguineous marriage, presented to medical attention with spastic paraparesis, mental
retardation, and epilepsy. Clinical testing included magnetic resonance imaging (MRI),
electromyography (EMG), electroencephalogram (EEG), cerebrospinal fluid analysis,
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and other specific laboratory examinations such as routine blood work, blood thyroid
hormone, ammonium, lactate levels, urine analysis.

Parents of the affected children were normal and consanguineous, providing evidence for
an autosomal recessive inheritance pattern. Affected status was assigned after clinical
documentation of prominent lower followed by upper extremity paraparesis with long
(pyramidal) tract signs (spasticity, hyperreflexia, and bilateral Babinski sign), and
epileptic discharges on electroencephalogram (EEG) (Figure 8).

Case 1 (V-1)

The index case was a four year-old female, a product of a consanguineous marriage, who
presented with neurological decline. The patient was neurologically normal until the age
of 6 months when parents became concerned with the child’s lack of interactivity. By the
age of 9 months, the child developed seizures which were controlled medically. On
neurologic examination, the patient demonstrated motor and mental retardation, spasticity
in the lower limbs, hyperreflexia, and an inability to sit without support. An MRI
revealed a thinned corpus callosum on coronal T2 and sagittal T1 imaging (Figure 9).

Case 2 (V-2)

The second affected was the brother of the index case, a twelve year-old male. The
patient developed normally but, as with Case 1, began having seizures at 10 months of
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age. He also suffered from mental retardation, spasticity in lower and upper limbs,
aphasia, hyperreflexia, and an inability to sit without support (imaging unavailable).

Case 3(V-3)

The third affected individual was a first cousin of the index case, also a product of a
consanguineous marriage. This ten-year-old boy presented with seizures and mental
retardation at age 6 months. He had difficulty swallowing solid food. Neurological
examination revealed mental retardation, spasticity in the lower limbs, hyperreflexia, and
inability to sit without support. MRI revealed mild, diffuse atrophy of grey and white
matter with a thinned corpus callosum (Figure 9).

In all 3 patients, EEG studies showed myoclonic generalized epileptic discharges.
Laboratory values provided no evidence for a lysosomal, mitochondrial, or peroxisomal
disorder or a disturbance of amino acid or organic acid metabolism. CSF analysis was
unremarkable.

Single Nucleotide Polymorphism Genotyping

We performed array-based genotyping on all available affected individuals and their
parents (n=7). The 50K SNP arrays provide estimated information with a mean marker
distance of 26 kb with an average of 53,970 genotypes scored per subject (SNP call-rates
ranged between 92%–97%). Multipoint linkage analysis demonstrated a mean LOD
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score of > 3 (maximum: 3.6287) within a 9.8 cM region between markers rs10518676
and rs2129773 on chromosome 15q15-q21 (Figures 10 and 11).

Linkage Using Microsatellite Short Tandem Repeat Markers

The linkage interval was verified and confirmed using seven highly polymorphic di and
tetranucleotide microsatellite repeats across our linkage interval. As expected, the
parents were heterozygous for the affected haplotype while the children with the HSPTCC phenotype were homozygous for the affected haplotype (Figure 8).

Mutation screen

Screening of the candidate genes within the linkage interval, SPATA5L1 and SEMA6D
failed to reveal any polymorphisms that segregated with the phenotype (data not shown).

Array CGH for Copy Number Analysis

Whole genome aCGH and chromosome 15-specific aCGH identified several copy
number variations throughout the genome. None of these variations, however, were
within the linkage interval and none segregated with the disease (Figure 12).
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Disorders of Cortical Organization

Our laboratory has collected 55 familial and sporadic cases of these disorders, including
20 cortical developmental anomalies, 19 cases of polymicrogyria, 8 cases of
schizencephaly, and one case of Greig cephalopolysyndactyly and cerebral cavernous
malformations (presented below).

Greig Cephalopolysyndactyly and Cerebral Cavernous Malformation

Background

Greig cephalopolysyndactyly (GCPS) is a syndrome characterized by polydactyly,
macrocephaly, and hypertelorism. Patients with severe GCPS can also present with
mental retardation, seizures, and hydrocephalus. Mutations in GLI3 at the chromosome
7p14 locus have been shown to cause GCPS (68).

Cerebral cavernous malformations (CCM) are abnormally dilated vascular channels,
lined by a single layer of endothelium, that are prone to leakage resulting in cerebral
hemorrhage. When symptomatic, the clinical manifestations can include headache,
seizure, and neurological deficits. The heritability of CCM has been well established,
and both familial and sporadic forms have been described. To date, three genes when
mutated have been shown to cause CCM: CCM1 on chromosome 7q21 (KRIT1) (69),
CCM2 on 7p13 (Malcavernin) (70, 71), and CCM3 on 3q26 (PDCD10) (72, 73).
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Our group reported the case of a patient who presented with a novel syndrome combining
the clinical hallmarks of CCM and GCPS (74). High resolution CNV analysis, or
comparative genome hybridization (aCGH), was used to identify the causal deletion on
chromosome 7p that resulted in the heterozygous loss of both the GLI3 and CCM2
transcripts.

Phenotype Assessment

This 32-month-old girl presented to Yale University with a history of developmental
delay. The mother’s pregnancy and delivery were uncomplicated, and the child was born
vaginally at a gestational age of 40 weeks (APGAR scores: 8 at 1 minute and 9 at 5
minutes). The family had no history of mental retardation, infant deaths, or multiple
spontaneous abortions. The patient has two older siblings who were noted to be
developmentally normal and without medical problems.

On examination the patient exhibited hypotonia with dysmorphic facial features, bilateral
polysyndactyly of the great toes (Figure 6), proptosis of the left eye, and a wide-based
stance. Her height and weight were in the 25th percentile, whereas her head
circumference was in the 90th percentile. She had a prominent forehead, synophrys, mild
thoracolumbar kyphosis, and a noncommunicating sacral dimple. Her neurological
examination was nonfocal.
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The facial features, hypotonia, and developmental delay indicated the possibility of a
genetic syndrome involving polydactyly. To rule out chromosomal abnormalities, Gbanded karyotyping was performed and was found to be normal (46, XX). The x-ray
film studies confirmed bilateral polydactyly and showed normal hands and a kyphotic
spine (Figure 6).

At age 4, seizures developed and the patient underwent additional neurological
examination and brain imaging, which revealed the presence of multiple CCMs. The
child was referred to the Yale Neurovascular Center. Axial T1-weighted MR imaging
demonstrated multiple CCMs in the periventricular region as well as the subcortical
parietal and frontal lobes (Figure 6). On detailed examination, we noted mild gyral
abnormalities consisting of possible asymmetry of the central sulci (Figure 6).

Array CGH for Copy Number Analysis

Given the current overlap in clinical features between CCM and GCPS, the known
involvement of GLI3 on chromosome 7p in the latter syndrome, the recent identification
of causal deletions of CCM2 in some patients with CCM (71), and a normal G-banded
karyotype in this patient, we elected to utilize array CGH to search for CNVs leading to
this clinical picture. Array CGH revealed no CNVs in the regions of CCM1 or CCM3
(Figure 7). However, a possible deletion was detected at the CCM2 locus on
chromosome 7p, consisting of 466 probes with an average log2 intensity of less than
20.5, which exceeded the cutoff for statistical significance of 20.3. The putative deletion
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covered 3 M base pairs mapping from 41.9 to 45 million bp on the short arm of the
chromosome.

Quantitative PCR

Quantitative PCR confirmed a heterozygous deletion encompassing the genes CCM2 and
GLI3 (Figure 7) as well as several intervening genes, including HECWI, CAMK2B, and
NPCL1 (Table 4). The quantitative RT-PCR analysis also confirmed two normal copies
of the genes centromeric (IGFBP1, TBRG4, ADCY1, and IGFBP3) and telomeric
(INHBA and CDC2L5) to the affected interval.
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DISCUSSION

The results of the three studies presented above demonstrate the utility of SNP
genotyping and CNV analysis in uncovering the genetic basis of MCD. Specifically,
three diseases are presented in this manuscript: infantile neuroaxonal dystrophy, Greig
cephalopolysyndactyly, and hereditary spastic paraparesis.

In the familial case of infantile neuroaxonal dystrophy, our results are the third, after
Morgan et al. and Khateeb et al., to implicate PLA2G6 as being associated with the
disorder. The two novel mutations presented in this study along with the mutations in
Morgan et al. will prove useful clinically in the diagnosis of INAD, which currently relies
on nonspecific histologic findings on invasive biopsy. A recent paper in Seminars in
Pediatric Neurology stated that once INAD is suspected, DNA testing should be utilized
to confirm the diagnosis (81). In the future, genetic testing for this disease may replace
tissue biopsy, which can be avoided altogether except in cases where testing fails to
demonstrate a PLA2G6 mutation.

The affected individuals in the INAD study, unlike a number of the individuals in
Morgan et al., did not have high iron concentrations in the basal ganglia. The possibility
exists that these represent two distinct disease processes: INAD without brain iron and
INAD with brain iron. Nevertheless, PLA2G6 mutations have been shown, in this and in
previous findings, to be associated with INAD regardless of brain iron concentration.
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Calcium-independent phospholipase A2, the protein product of PLA2G6, is involved in
cell membrane homeostatis, arachidonic acid release, and leukotriene / prostaglandin
synthesis. It has been hypothesized that a loss of function mutation in PLA2G6 and the
subsequent defect in phospholipase A2 lead to excessive levels of membrane
phosphatidylcholine, which may result in the axonal pathology observed in INAD (35).
The specificity of this effect on the central and peripheral nervous systems raises the
question of PLA2G6 expression patterns. Currently, our laboratory is studying the
expression of PLA2G6 in order to shed light on this issue.

In the case of the patient with Greig cephalopolysyndactyly and cerebral cavernous
malformations, our laboratory reported a seemingly new clinical syndrome resulting from
a heterozygous deletion affecting chromosome 7p14-13. Our results illustrate the utility
of high-resolution array CGH in the study of suspected genetic syndromes. We used this
technique to investigate possible variations in the three established CCM loci (7p, 7q, and
3q). We found a statistically significant CNV on chromosome 7p, which was then
confirmed on quantitative RT-PCR to be a deletion of the interval containing the genes
CCM2 (causing CCMs) and GLI3 (causing GCPS).

Greig cephalopolysyndactyly syndrome is characterized by polydactyly, hypertelorism,
developmental delay, syndactyly, and macrocephaly. Moreover, two additional
syndromes with clinical features overlapping those of GCPS have been described.
Acrocallosal syndrome, like GCPS, is characterized by polysyndactyly, macrocephaly,
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and hypertelorism; however, patients with this syndrome also show dysgenesis of the
corpus callosum (82) and tend to have more severe developmental delay than those with
GCPS. Pallister–Hall syndrome shares with GCPS the key features of postaxial
polydactyly and developmental delay but does not include hypertelorism or
macrocephaly (68). The case reported by our laboratory is the first instance of GCPS
associated with CCMs as part of a broader syndrome marked by a 7p14-13 deletion.

In addition to CCM2 and GLI3, deletions on several other genes within the interval were
confirmed on quantitative RT-PCR (Table 4). However, bioinformatic analysis of
sequence conservation of the brain-expressed genes within this region identified only
GLI3 as having a strongly conserved element (83) or highly conserved element (84)
across vertebrates. This result suggests that these other transcripts within this interval
may not be under strong stabilizing selection. In conjunction with the absence of any
additional clinical features beyond those attributable to CCM or GCPS in the affected
patient, this analysis suggests that heterozygous deletions of these additional transcripts
may be well tolerated.

In the report on this patient, we characterized a novel syndrome consisting of CCMs,
polydactyly, developmental delay, and hypertelorism resulting from a 7p14-13 deletion
including the genes CCM2 and GLI3. Our identification of the causative submicroscopic
deletion, which was not identified using standard genetic testing methods, suggests that
high resolution chromosomal analysis and neuroimaging studies are indicated when
evaluating syndromic patients with neurological problems.
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This manuscript also presents a familial case of hereditary spastic paraparesis. In this
investigation, a member of our laboratory identified a family from eastern Turkey with
autosomal recessive HSP, epilepsy, mental retardation, and a thinned corpus callosum
(TCC) on MRI demonstrating linkage to the SPG11 locus at 15q15.1-q21.3, a region
between 38.1 - 51 Mb. The clinical criteria for HSP-TCC are defined as normal motor
development followed by a slowly progressive spastic paraparesis, mental retardation,
and a very thin corpus callosum on imaging (64-66). Other clinical signs that have been
reported include extrapyramidal signs, hyperreflexia, dysphagia, dysarthria, amyotrophy,
urinary incontinence, muscle atrophy, and peripheral neuropathy with cortical atrophy
and white matter changes on imaging (60-63). The average age of onset has been
reported to be in the second decade (60).

In HSP, significant phenotypic variability exists within affected members of families with
respect to clinical signs and radiographic signs. For example, some affected patients
demonstrate various degrees of thinning of the corpus callosum on MRI, thought to
represent a progressive finding of neuronal loss (60, 62, 63, 66). The family reported
here differs from those previously reported with respect to the uniformly early onset of
disease (in the first year of life) including epileptic seizures and a mildly-thinned corpus
callosum on MRI, further expanding the phenotype. Interestingly, no cases of epilepsy
were reported in any of the families demonstrating linkage to SPG11. The only prior
reported case of HSP with epilepsy was from the family with the so-called autosomal
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dominant “SPERM” syndrome (58), though others have reported affected patients with
seizures late in disease progression (85).

Linkage analysis of the SPG11 locus for HSP was first reported by Martinez Murillo et
al. (65) in 7 families from Italy and North America, between markers D15S1007 and
D15S1012 on chromosome 15q13-15, a region of approximately 6.9 cM corresponding to
5 Mb on chromosome 15 (Figure 13). This linkage region was subsequently expanded
(64) to between markers D15S971 and D15S117, a region of 26.7 cM corresponding to
23 Mb in 10 Japanese families with HSP-TCC. Originally described in the Japanese
population (85-87), there have been several reports in the literature of families with HSPTCC from different ethnicities, with the majority of families appearing to originate from
the Mediterranean region (60-63, 65). Genetic linkage results in many of these families
have confirmed or narrowed the SPG11 locus (60, 62, 63, 66). A recently published
paper by Olmez et al. (61) reported linkage in 4 Turkish families in a region between
markers D15S968 and D15S132. The authors argue that their results narrow the
centromeric end of the region and, in effect, exclude the region defined by Martinez
Murillo et al. (65). Our linkage data confirm the results of Olmez et al. (61), also
excluding the first reported interval (Figure 13).

Chromosomal copy number alterations can lead to over activation or inactivation of
genes in humans leading to cancer or disease phenotypes. Comparative Genomic
Hybridization (CGH) is a method to detect chromosomal copy number by comparing
hybridization intensity of a patient’s DNA to a control DNA sample (88) and has become
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an important tool in rapid identification of functional mutations within linkage intervals
(89-91). In the case of a family with HSP, we hypothesized that CNVs within the linkage
interval might be causative of the disease phenotype. We performed array-based wholegenome and chromosome 15-specific CGH in the family. Analysis of the array results
did not show any CNV within the linkage interval in affected patients. Furthermore,
mutational analysis of the potential candidate genes SPATA5L1 and SEMA6D in this
region did not reveal any causative mutations (60, 63).

In addition to HSP, a second congenital neurological disorder demonstrates linkage to the
same interval as SPG11. Amyotrophic lateral sclerosis type 5 (ALS5) is characterized by
gait disturbance, spasticity, mental retardation, and severe bulbar and pseudobulbar
findings and demonstrates linkage between markers D15S146 and D15S123 (92). It is
possible that this phenotype is a part of the same spectrum of neurological disorders as
HSP-TCC, caused by different mutations within the same gene (that ALS5 is an allelic
disorder to HSP-TCC) supporting the idea that HSP-TCC represents a syndrome with
broad phenotypic and genetic heterogeneity. This hypothesis is plausible as it was
previously demonstrated that ALS2 is allelic to infantile ascending hereditary spastic
paralysis (IAHSP) (93). More compelling is the fact that many families with autosomal
recessive HSP-TCC (families with affected members fitting the clinical criteria of the
syndrome) exclude by linkage the reported SPG11 locus (60, 62, 66). This clearly argues
in favor of genetic heterogeneity of the disorder.
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Our results for HSP confirm previously published linkage analysis in families
demonstrating linkage to the SPG11 locus on 15q and demonstrate the absence of CNV
within the linkage interval in this family. The phenotype reported here adds to the broad
spectrum of clinical findings within the HSP-TCC syndrome. These results, when
dovetailed with those previously published, demonstrate phenotypic heterogeneity of a
common clinical entity with a common genetic cause. The explanation of phenotypic
variation within patients linking to the SPG11 locus is likely multifactorial and a
combination of non-genetic, compound genetic, and mutation-specific causes.

The three cases presented in this manuscript demonstrate the utility of molecular genetic
approaches, particularly SNP genotyping and CNV analysis, in uncovering the genetic
basis of neural developmental disease. In the familial case of INAD, our laboratory was
able to find two novel mutations in the PLA2G6 gene. In the sporadic case of GCPS and
CCM, CNV analysis using aCGH was used to identify the chromosome 7 deletion
affecting the GLI3 and CCM2 genes. These results establish this unique clinical
presentation as a novel syndrome combining the hallmarks of GCPS and CCM. Finally,
in the case of the Turkish family with HSP, high density SNP genotyping was used for
whole genome linkage analysis, allowing us to further narrow the previously established
linkage interval for this autosomal recessive disease. Although in this case we were not
able to identify a causative gene mutation, narrowing the interval of the SPG11 locus on
chromosome 15 will help guide future efforts to hunt the gene(s) responsible for HSP.

39
Our laboratory continues to perform mutational analysis on candidate genes in this locus
as well as other regions associated with neurologic disorders. The molecular genetic
approaches described in this manuscript will further enhance our understanding of the
pathophysiology of diseases of neural development.
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Figure 1: Parkinsonian family pedigree and linkage. a: Family pedigree (colored
shapes designate family members with Parkinsonism). b: Linkage analysis using SNP
microarrays demonstrates linkage with a LOD score of 5.08 (LOD > 3 represents
significance) to a region of chromosome 6 housing the parkin gene. Adapted from
Bayrakli et al. (15).
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Figure 2: Parkinsonian family copy number analysis. a: Scatter plot of whole genome
array-based comparative genome hybridization demonstrates a region within the linkage
interval predicting a homozygous microdeletion. Scattered points represent normalized
log2 ratios (y) for probes along the chromosome. A segment was considered to be
significant if y > 0.3 or y < -0.3. These results show a region with an average log2 ratio
(y) of -1.16, suggesting a homozygous deletion. b: Scatter plot of aCGH specific for
chromosome 6 demonstrates a higher density of probes and prediction of homozygous
microdeletion. The black bar represents the parkin gene. Adapted from Bayrakli et al.
(15).
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Figure 3: Parkinsonian family PCR deletion. a: PCR confirmation of the
microdeletion. The top image represents amplification using intronic primers
immediately flanking exon 4, confirming the presence of this exon in all family members.
The middle image demonstrates amplification using primers that flank exon 5, showing a
microdeletion in 3 affected siblings. b: This diagram illustrates the location of the
microdeletion in the parkin gene. Adapted from Bayrakli et al. (15).
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a

b

c

Figure 4: Images of malformations of cortical development. The diseases presented
in these image include corpus callosum hyperplasia, a disorder of cell proliferation (a);
subcortical band heterotopia or “double cortex,” a disorder of neuronal migration (b); and
polymicrogyria, a disorder of cortical organization (c).
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Figure 5: Two sporadic cases of INAD. In the first kindred, the dark circle represents a
young child affected with INAD. Her brother, who was also had INAD, has passed (dark
square with line). In the second kindred, a young child, the offspring of a
consanguineous marriage, is also affected with INAD.
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Figure 6: GCPS patient imaging. Radiographs obtained in a 32-month old girl,
demonstrating bilateral polysyndactyly of the great toes (a) and scoliosis of the spine (b).
Serial axial T1 (c) and T2-weighted (d) MR images obtained in the patient at 4 years of
age, revealing subcortical CCMs (arrows) in the right parietal and left frontal lobes as
well as a left periventricular CCM. Reformatted MR image (e) showing a normal central
sulcus on the left side (arrow) and an asymmetrically formed central sulcus on the right.
Adapted from Bilguvar et al. (74).
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Figure 7: GCPS patient CNV and QPCR results. Graphs depicting the results of CNV
analysis. On chromosome 7, a deletion was revealed within the CCM2 locus (a,
arrowhead), but no apparent CNVs within the CCM1 locus (a, arrow). With this analysis,
gene deletions are represented by negative log2 ratios of the signal intensity relative to
normal. To be significant, the log2 ratio (y axis) must be less than 20.3. The log2 ratio at
the CCM2 region is less than 20.5, indicating the presence of a deletion in that locus.
There is no CNV within the CCM3 locus (b). Bar graphs of quantitative RT-PCR of
CCM2 (c) and GLI3 (d) showing approximately half of the relative amplification of each
respective gene amplicon, consistent with the presence of a heterozygous deletion in the
affected patient (2222-1) within the CNV interval. The controls and parents (father 22222 and mother 2222-3) demonstrate full amplification of each respective gene amplicon.
Adapted from Bilguvar et al. (74).
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Figure 8: HSP family pedigree with STS marker haplotypes. Filled symbols show
affected individuals, males are represented with square symbols, females with circles.
The pattern, given the consanguinity, suggests autosomal recessive inheritance. Below
affected family members V1-3 and their respective parents note the haplotype as
determined by STS marker genotyping between markers D15S994 and D15S1016.
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Figure 9: HSP cases V1 (a-c) and V3 (d-f) imaging. Patient V1 coronal (a) and axial
(b) T2-weighted MRI images through the thalamus and 3rd ventricle demonstrate diffuse
enlargement of the subarachnoid spaces along the convexities likely due to gray and
white matter loss. Midline sagittal (c) T1-weighted MRI demonstrates the thinned corpus
callosum. The cerebellum, pons, and medulla appear normal. Patient V3 coronal (d) and
axial (e) T2-weighted MRI images through the thalamus and 3rd ventricle again
demonstrate diffuse enlargement of the subarachnoid spaces along the convexities likely
due to gray and white matter loss. Midline sagittal (f) T1-weighted MRI similarly
demonstrates the thinned corpus callosum.
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Figure 10: HSP family array-based SNP genotyping results. Genotyping results using
the GeneChip Mapping 50K XbaI Array. Figure demonstrates multipoint linkage
analysis plots for each chromosome. X axis = cM distance along the chromosome. Y
axis = LOD score. Results are plotted after analysis using Chunky followed by the
Allegro software. * denotes chromosome 15 results.
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Figure 11: HSP family validated linkage interval of 15q15.1-q21.3. Graphical
demonstration of multipoint linkage analysis demonstrating a LOD score of > 3
(maximum: 3.6287) within a 9.8 cM region between markers rs10518676 and rs2129773
on chromosome 15q.
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Figure 12: HSP family whole-genome and chromosome 15-specific aCGH. Graphical
representation of whole-genome (a) and chromosome 15-specific (b) copy number
variation (CNV) analysis using array-based comparative genomic hybridization (aCGH).
Detailed analysis did not demonstrate any CNVs within the sensitivity of the assay.
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Figure 13: HSP family schematic of chromosome 15 linkage results for SPG11. Xaxis designates the distance and position along chromosome 15q in million base pairs.
The top bar represents the linkage interval reported in this manuscript (3). The remainder
of the linkage intervals reported for SPG11 are shown (4-9) as are the two known
neurological syndromes within the region (Andermann syndrome and ALS5; 1,2).
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Table 1: Classification of diseases of cortical development.
I.

II.

III.

IV.

Malformations due to abnormal neuronal and glial proliferation or
apoptosis
a. Decreased proliferation / increased apoptosis or increased proliferation /
decreased apoptosis – abnormalities of brain size
i. Microcephaly with normal to thin cortex
ii. Microlissencephaly (extreme microcephaly with thick cortex)
iii. Microcephaly with extensive polymicrogyria
iv. Macrocephalies
b. Abnormal proliferation (abnormal cell types)
i. Nonneoplastic
1. Cortical hamartomas of tuberous sclerosis
2. Cortical dysplasia with balloon cells
3. Hemimegalencephaly
ii. Neoplastic (associated with disordered cortex)
1. Dysembryoplastic neuroepithelial tumor
2. Ganglioglioma
3. Gangliocytoma
Malformations due to abnormal neuronal migration
a. Lissencephaly / subcortical band heterotopia spectrum
b. Cobblestone complex / congenital muscular dystrophy syndromes
c. Heterotopia
i. Subependymal (periventricular)
ii. Subcortical (other than band heterotopia)
iii. Marginal glioneuronal
Malformations due to abnormal cortical organization (including late
neuronal migration)
a. Polymicrogyria and schizencephaly
i. Bilateral polymicrogyria syndromes
ii. Schizencephaly (polymicrogyria with clefts)
iii. Polymicrogyria or schizencephaly as part of multiple congenital
anomaly / mental retardation syndromes
b. Cortical dysplasia without balloon cells
c. Microdysgenesis
Malformations of cortical development, not otherwise classified
a. Malformations secondary to inborn errors of metabolism
i. Mictochondrial and pyruvate metabolic disorders
ii. Peroxisomal disorders
b. Other unclassified malformations
i. Sublobar dysplasia
ii. Others

Adapted from Barkovich et al. (21).
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Table 2: Genetic basis of malformations of cortical development.
Syndrome
Autosomal recessive periventricular
heterotopia / micrcocephaly
Autosomal recessive periventricular
heterotopia / micrcocephaly

Locus

Gene

Protein

8p23

MCPH1

1q31

ASPM

Autosomal recessive microcephaly

9q34

CDK5RAP2

Autosomal recessive microcephaly
Autosomal recessive periventricular
heterotopia / micrcocephaly

13q12.2

CENPJ

Microcephalin
Abnormal spindle-like
microcephaly
CDK-5 regulatory-associated
protein 2
Centromere-associated
protein J

20q13.13

ARFGEF2

17q25.3
3q22q24
Xq22.3q23
Xq22.3q23

SLC25A19

Amish lethal microcephaly
Seckel syndrome 1
Isolated lissencephaly sequence
Subcortical band heterotopia
Miller-Dieker syndrome
Isolated lissencephaly sequence
Subcortical band heterotopia
Lissencephaly with cerebellar hypoplasia
X-linked lissencephaly with abnormal
genitalia
Fukuyama congenital muscular dystrophy
Muscle-eye-brain disease
Muscle-eye-brain disease
Congenital muscular dystrophy
Congenital muscular dystrophy
Walker-Warburg syndrome
Walker-Warburg syndrome
Walker-Warburg syndrome
Bilateral periventricular nodular
heterotopia
Bilateral periventricular nodular
heterotopia + microcephaly
Bilateral periventricular nodular
heterotopia
Tuberous sclerosis chromosome 1
Tuberous sclerosis chromosome 2
Bilateral frontoparietal polymicrogyria
Warburg microsyndrome 1
Bilateral perisylvian polymicrogyria

Adapted from Barkovich et al. (21).

ATR

ARFGEF2
Nuclear mitochondrial
deoxynucleotide carrier
Ataxia telangiectasia and
Rad3 related protein

DCX-XLIS

DCX

DCX-XLIS
Several
contiguous
LIS1
LIS1
RELN

Xp22.13
9q31
1p33p34
19q13.3
19q13.3
22q12.3q13.1
9q34.1
19q13.3
9q31

ARX
FCMD

DCX
PAFAH1B1, 14-3-3 and
others
PAFAH1B1
PAFAH1B1
Reelin
Aristaless-related homeobox
protein
FCMD or Fukutin

POMGnT1
FKRP
FKRP

Unknown
Fukutin-related protein
Fukutin-related protein

LARGE
POMT1
FKRP
FCMD

O-Mannosyl-transferase 1
Fukutin-related protein
FCMD

Xq28

FLNA

Filamin-A

20q13.3

ARFGEF2

BIG2

5p15
9q32
16p13.3
16q13
2q21.3
Xq28

Unknown
TSC1
TSC2
GPR56
RAB3GAP
Unknown

Unknown
Hamartin
Tuberin
Unknown

17p13.3
17p13.3
17p13.3
7q22

Unknown
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Table 3: Examples of recent medical applications of SNP genotyping microarrays.
Purpose of Study
Linkage analysis of prostate
cancer
Linkage analysis of
rheumatoid arthritis
Homozygosity mapping in
erythrokeratodermia
variabilis
Allelic imbalance in bladder
cancer
Copy-number and allelic
alteration in cancer cells
Linkage and association
study of systemic lupus
erythematosus
Association study of HDLcholesterol levels
Adapted from Syvanen et al. (5).

Microarray Number of
SNPs
GeneChip
10,000
10K
GeneChip
10,000
10K
BeadArray
4,700

Number of
Samples
167 (families)
157 (families)
20

GeneChip
10K
GeneChip
10K

10,000

37

10,000

42

SNPstream

45

1,915

GeneChip

7,300

6
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Table 4: Quantitative PCR results showing deletions in CCM2 and GLI3 as well as
several intervening genes.
Gene
CDC2L5
INHBA
GLI3
GLI3
HECW1
CAMK2B
NPCL1
CCM2
CCM2
IGFBP1
TBRG4
ADCY1
IGFBP3

Start base pair
39763349
41501843
41776920
41776920
43124602
44032137
44325377
44813092
44813092
45701194
44912940
45387361
45725089

Adapted from Bilguvar et al. (74).

End base pair
39908385
41515946
42036135
42036135
43376178
44138464
44354154
44889290
44889290
45706506
44924557
45535952
45734111

Exon
13
2
2
12
8
19
11
4
9
2
2
13
2

Result
normal
normal
deletion
deletion
deletion
deletion
deletion
deletion
deletion
normal
normal
normal
normal

